Camrelizumab anti-PD-1 with or without Chemotherapy for NPC

Camrelizumab anti-PD-1 with or without chemotherapy for NPC

Camrelizumab (SHR-1210, Hengrui Medicine), a novel programmed death 1 (PD-1) inhibitor, plus gemcitabine and cisplatin showed a manageable toxicity profile with promising, preliminary anti-tumour activity in treatment-naïve Chinese nasopharyngeal carcinoma (NPC) patients. Larger, randomised controlled trials may provide further insight into the role of anti-PD1 for NPC, wrote the authors in the Lancet Oncology.

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

The combination capmatinib (INC280, Novartis) plus gefitinib (Iressa®, AstraZeneca) showed promising, early phase efficacy in patients with mesenchymal-epithelial transition factor (MET)-dysregulated and epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

CARsgen Therapeutics, a Shanghai-based clinical-stage immune-oncology company committed to developing Chimeric Antigen Receptor T (CAR-T) cell therapies for cancer, presented preliminary data of their first-in-class CAR-Claudin18.2 T-cell clinical trial in pancreatic and gastric cancer patients during the 2018 CAR-TCR Summit in Boston.

DRIVER connects cancer patients in China and the United States to the best care

SAN FRANCISCO and SHANGHAI, Sept. 6, 2018/PRNewswire/ -- Today, Driver, a global technology platform that connects cancer patients to the best treatments, launches in the United States and China. Driver's platform enables any patient, anywhere in the world, to access treatment options across an unprecedented network of cancer centres without leaving home.

PolyU Researchers Develop Novel Self-fitting Scaffold for Bone-Regeneration

HONG KONG, August 15, 2018 /PRNewswire/ -- A group of researchers from the Hong Kong Polytechnic University (PolyU) in close collaboration with Sichuan University have successfully designed and manufactured a novel bone scaffold that can be safely implanted into bone defects, induce bone-regeneration, and enhance the recovery of bone injuries and fractures.

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

HONG KONG, CHINA - 13 August 2018 - Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), announced that its innovative in-house developed oncology drug pirotinib has commenced into Phase II Clinical testing in China following the completion of a Phase I clinical trial in three renowned cancer research centres in the United States. 

Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

Crizotinib in Asian NSCLC patients with ROS1 alterations was associated with a 71.7% objective response rate (ORR) with a median duration of response (DOR) of 19.7 months (95% CI, 14.1 months - not reached). Learn more about the results with crizotinib in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements.

Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China

There is no excerpt because this is a protected post.

Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Xiong Lize on the status of ERAS in China

There is no excerpt because this is a protected post.

25th Annual Meeting of the Chinese Society of Anaesthesiology

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology. Impressions of the 25th Annual Meeting of the Chinese Society of Anaesthesiology - CSA2017 - 中华医学会第25 次全国麻醉学术年会